Roswell Park Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Roswell Park Cancer Institute sits in the top decile of US sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count).
Roswell Park Cancer Institute: 365 sponsored US clinical trials, 57 recruiting.
Roswell Park Cancer Institute sponsors 365 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 200 completed. 7 of these trials are in Phase 3-4 (later-stage) and 238 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 9 trials.
Top-decile sponsor footprint
Roswell Park Cancer Institute ranks in the top decile of sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
200 of 279 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
365 total, page 1 of 8
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT07489287
New York Better Breathing Study
NCT06869447
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
NCT06202066
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
NCT07017829
Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors
NCT06565260
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effects
NCT07107139
Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance
NCT07439471
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
NCT06434064
Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers
NCT06977503
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
NCT07214298
Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
NCT07402577
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06871410
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
NCT06863402
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
NCT06821997
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
NCT06733363
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
NCT06995508
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
NCT07182240
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
NCT06816459
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand
NCT07102082
A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patients, Financial Compass Trial
NCT06896695
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
NCT06855706
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
NCT06627751
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
NCT06833255
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06622005
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
NCT07167225
Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT06798701
MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
NCT06323044
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
NCT06733350
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT06305598
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
NCT06350500
A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York
NCT06681077
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
NCT06074666
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
NCT06306638
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT06563388
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
NCT06206863
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
NCT06307548
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05231122
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
NCT06414317
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
NCT06320717
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
NCT05292521
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
NCT05787834
Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
NCT05893940
Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy
NCT04646434
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT04919629
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
NCT05651594
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT04348747
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
NCT06456411
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
NCT05312255
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
NCT04696575
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT04511039
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 123 |
| Phase 2 | 115 |
| Phase 3 | 5 |
| Phase 4 | 2 |
What is open in the Roswell Park Cancer Institute pipeline
57 recruiting of 365 indexed (16% open); 200 completed (55%).
Phase mix: 7 late (III/IV) vs 238 early (I/II) (early-phase heavy).
Top condition: Leukemia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Roswell Park Cancer Institute: open-pipeline peers nationwide
Peers matched on 365 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Roswell Park Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 365 trials (± recruiting share)
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Cambridge Health Alliance · 16% recruiting · 45 trials
- Louisiana State University Health Sciences Center in New Orleans · 16% recruiting · 45 trials
- University of Southern California · 16% recruiting · 617 trials
- Incyte Corporation · 15% recruiting · 239 trials
Related
What to do with this Roswell Park Cancer Institute page
365 registered trials is a research-attention snapshot, not an endorsement of Roswell Park Cancer Institute or any single study.
- 57 of Roswell Park Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Roswell Park Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Roswell Park Cancer Institute pipeline card: 365 registered trials from official public datasets.Report a data error.